Helius Medical Technologies - Home


Call us: +1 877-564-0008


Stock Quote - HSDT

*Delayed quote courtesy of Google.

The company became public in June 2014 and raised money to perform formal registrational clinical trials and other scientific activities to support regulatory clearance in the US, Canada, Europe and Australia. Helius achieved clearance for PoNS™ in Canada in Q4 2018.

Helius continues to pursue beyond-reproach scientific studies to support its technology and looks forward to responsibly driving access to PoNS Treatment™ to help improve the lives of people dealing with symptoms of neurological disease and trauma in the future.